MedTrace Logo

U-LABA/ICS Effects on Exercise Performance, Indacaterol

NCT06067100 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-04-09

No results posted yet for this study

Summary

The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate

Conditions

  • Exercise Performance

Interventions

DRUG

Indacaterol and Mometasonefluroate (low dose)

Participants are administered 125 µg indacaterol + mometasonefluroate

DRUG

Placebo

Participants are administered placebo

DRUG

Indacaterol and Mometasonefluroate (high dose)

Participants are administered 500 µg indacaterol + mometasonefluroate

Sponsors & Collaborators

  • Morten Hostrup, PhD

    lead OTHER

Principal Investigators

  • Morten Hostrup, PhD · University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-15
Primary Completion
2026-07-15
Completion
2026-12-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06067100 on ClinicalTrials.gov